```html

Benign Prostatic Hyperplasia (BPH) – A Comprehensive Medical Guide

Overview

Benign prostatic hyperplasia (BPH) is a non‑cancerous enlargement of the prostate gland that occurs in most men as they age. The prostate surrounds the urethra (the tube that carries urine out of the bladder). When the gland enlarges, it can compress the urethra and interfere with normal urine flow.

• Who it affects: Primarily men aged 50 years and older. By age 60, about 50 % of men show some degree of enlargement; by age 85, the prevalence rises to 80–90 %.<sup>1</sup>
• Prevalence worldwide: In the United States, >10 million men are diagnosed with BPH, accounting for roughly 1 in 3 outpatient urology visits.<sup>2</sup>
• Why “benign”? The term indicates that the growth is not cancerous. BPH does not turn into prostate cancer, although both conditions can coexist.

Symptoms

Symptoms are collectively called “lower urinary tract symptoms” (LUTS). They can be “storage” (related to bladder filling) or “voiding” (related to emptying). Not every man with an enlarged prostate experiences symptoms; severity varies.

Storage symptoms

• Frequency: Need to urinate more often, especially at night (nocturia – >2 trips/night is common).
• Urgency: Sudden, compelling urge to urinate that is difficult to postpone.
• Urgency incontinence: Involuntary leakage after a strong urge.

Voiding symptoms

• Weak stream: Decreased force of urine flow.
• Intermittent stream: Flow starts and stops.
• Straining: Need to push hard to start urination.
• Hesitancy: Delay before the stream begins.
• Incomplete emptying: Feeling that the bladder is not fully emptied.
• Dribbling: Post‑void leakage.

Complicated presentations

• Acute urinary retention (sudden inability to urinate).
• Recurrent urinary tract infections (UTIs) due to residual urine.
• Bladder stones or kidney damage from chronic back‑pressure.

Causes and Risk Factors

The exact cause of BPH is not fully understood, but hormonal changes that accompany aging appear central.

Pathophysiology

• Androgen involvement: Dihydrotestosterone (DHT), a metabolite of testosterone, stimulates prostate cell growth.
• Estrogen balance: With age, circulating estrogen rises relative to testosterone, promoting hyperplasia.
• Growth factors: Insulin‑like growth factor‑1 (IGF‑1) and fibroblast growth factor may contribute.

Risk factors

• Age: The most powerful predictor; risk doubles approximately every decade after 50.
• Family history: First‑degree relatives with BPH increase risk 2‑3×.<sup>3</sup>
• Ethnicity: Higher prevalence in African‑American men; lower in Asian populations, possibly reflecting dietary and genetic differences.
• Obesity & metabolic syndrome: Insulin resistance correlates with larger prostate volume.
• Cardiovascular disease & hypertension: Shared vascular mechanisms may influence prostatic growth.
• Medications: Chronic use of antihistamines, decongestants, or anticholinergics can worsen urinary symptoms.

Diagnosis

Diagnosis combines a symptom assessment with objective testing to rule out infection, bladder disease, or cancer.

Clinical assessment

• History & symptom score: The International Prostate Symptom Score (IPSS) quantifies severity (0–35). A higher score guides treatment intensity.
• Physical exam: Digital rectal exam (DRE) evaluates prostate size, consistency, and nodules that might suggest cancer.

Laboratory tests

• Urinalysis: Checks for infection, blood, or glucose.
• Prostate‑specific antigen (PSA): Elevated PSA can be due to BPH, prostatitis, or cancer; levels help decide if a biopsy is needed.

Imaging & urodynamic studies

• Transrectal ultrasound (TRUS): Measures prostate volume; >30 mL often correlates with symptomatic BPH.
• Bladder scan (post‑void residual, PVR): Detects retained urine; >100 mL suggests obstruction.
• Uroflowmetry: Records urine flow rate; <15 mL/s is considered reduced.
• Cystoscopy: Direct visual inspection of urethra and bladder; reserved for atypical cases.

Treatment Options

Treatment is individualized based on symptom severity, prostate size, patient age, comorbidities, and personal preference.

Watchful waiting

• Suitable for mild (IPSS ≤7) or stable symptoms.
• Includes lifestyle modification and periodic monitoring every 6–12 months.

Medications

1. α₁‑adrenergic blockers (e.g., tamsulosin, alfuzosin, doxazosin)
   • Relax smooth muscle in the prostate neck and bladder neck, improving urine flow within days.
   • Common side effects: dizziness, orthostatic hypotension, retrograde ejaculation.
2. 5‑α‑reductase inhibitors (5‑ARIs) (e.g., finasteride, dutasteride)
   • Block conversion of testosterone to DHT, shrinking the gland over 6–12 months.
   • Effective for prostates >30 mL; may reduce need for surgery.
   • Side effects: decreased libido, erectile dysfunction, breast tenderness; rare: high‑grade prostate cancer risk (controversial).
3. Combination therapy (α‑blocker + 5‑ARI)
   • Provides rapid symptom relief plus long‑term volume reduction.
   • Recommended by AUA and EAU for men with moderate‑to‑severe symptoms and enlarged prostates.
4. Phosphodiesterase‑5 inhibitors (e.g., tadalafil)
   • Can improve LUTS and erectile dysfunction simultaneously.
   • Used when sexual function is a concern.

Minimally invasive procedures

• Transurethral microwave thermotherapy (TUMT) & transurethral needle ablation (TUNA): Use heat to destroy excess tissue; outpatient, modest symptom improvement.
• UroLift (prostatic urethral lift): Permanent implants that compress lateral prostate tissue, preserving ejaculation function.
• Water‑vapour therapy (Rezūm): Radio‑frequency steam ablates tissue; durable symptom relief in many studies.

Surgical options

• Transurethral resection of the prostate (TURP): Gold‑standard for prostates 30–80 mL; removes tissue via resectoscope. Effective but carries risks of bleeding, retrograde ejaculation, and TURP syndrome.
• Holmium laser enucleation (HoLEP): Laser cuts prostate en bloc; suitable for very large glands (>80 mL) with less bleeding.
• Open or robotic simple prostatectomy: Reserved for massive prostates (>100 mL) or when minimally invasive methods fail.

Lifestyle & self‑care measures

• Limit caffeine and alcohol, especially in the evening.
• Schedule “timed voiding” (e.g., every 2–3 hours) to train the bladder.
• Maintain healthy weight and regular aerobic exercise.
• Consider double‑voiding: urinate, wait 30 seconds, then try again.

Living with Benign Prostatic Hyperplasia (BPH)

Managing BPH is a marathon, not a sprint. Below are practical tips to keep daily life comfortable.

Fluid management

• Drink 1.5–2 L of water daily, spread evenly; avoid large volumes before bedtime.
• Use a “bladder diary” for 3 days to identify patterns and trigger drinks.

Bladder training

• Gradually increase the interval between bathroom trips by 5–10 minutes.
• Practice “slow‑pull” technique: start urinating slowly to reduce urgency.

Pelvic floor exercises

• Kegel exercises strengthen urethral sphincter control, which may lessen leakage.
• Perform 3 sets of 10 contractions daily, holding each for 5 seconds.

Medication adherence

• Take α‑blockers in the morning (to avoid nighttime dizziness) and 5‑ARIs at the same time each day.
• Set phone reminders; discuss side effects promptly with your provider.

Regular follow‑up

• Every 6–12 months: repeat IPSS, PSA, and PVR if symptoms change.
• Report new blood in urine, fever, or sudden inability to urinate.

Emotional wellbeing

• Nighttime trips can disturb sleep; consider short naps and good sleep hygiene.
• Joining a support group (online or in‑person) normalizes the experience and offers coping strategies.

Prevention

While aging is inevitable, several modifiable factors may lower the risk or slow progression.

• Healthy diet: Emphasize fruits, vegetables, whole grains, and omega‑3 fatty acids (fish, walnuts). The Mediterranean diet is linked to lower BPH incidence.<sup>4</sup>
• Maintain a healthy weight: Obesity increases estrogen conversion and insulin resistance, both implicated in prostate growth.
• Regular physical activity: 150 min/week of moderate aerobic exercise reduces LUTS severity.
• Limit stimulants: Caffeine and alcohol can exacerbate urgency and frequency.
• Stay hydrated, but not over‑hydrated: Excess fluids increase bladder workload.
• Screening: Discuss PSA testing and prostate health with your clinician starting at age 45–50, especially if you have risk factors.

Complications

If BPH is left untreated or poorly managed, several serious sequelae can develop.

• Acute urinary retention (AUR): Sudden inability to pass urine; requires catheterization and often surgery.
• Chronic urinary retention: Leads to bladder distention, decreased contractility, and increased infection risk.
• Recurrent urinary tract infections: Stagnant urine promotes bacterial growth.
• Bladder stones: Form from concentrated urine left in the bladder.
• Kidney damage: Prolonged back‑pressure can cause hydronephrosis and renal insufficiency.
• Decreased quality of life: Sleep disruption, anxiety, and reduced ability to travel or engage in social activities.

When to Seek Emergency Care

References

1. Mayo Clinic. Benign prostatic hyperplasia (BPH) – Symptoms and causes. https://www.mayoclinic.org
2. Centers for Disease Control and Prevention. Urinary conditions: fast stats. https://www.cdc.gov
3. McVary, K. T. (2013). BPH: Epidemiology and risk factors. Urology. PMCID: PMC4281498
4. Leong, Q., et al. (2019). Mediterranean diet and lower urinary tract symptoms. Nutrition Journal. PMCID: PMC5986621
5. American Urological Association (AUA) Guideline: Management of BPH. 2022. https://www.auanet.org
6. European Association of Urology (EAU) Guidelines on BPH. 2023. https://uroweb.org

```